BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020

Haitham Hamoda; Susan R. Davis; Antonio Cano; Edward Morris; Sonia Davison; Nicholas Panay; Mary A. Lumsden; Tim Hillard; Tommaso Simoncini

doi:10.1177/2053369120983154

BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020

Haitham Hamoda, Susan R. Davis, Antonio Cano, Edward Morris, Sonia Davison, Nicholas Panay, Mary A. Lumsden, Tim Hillard, Tommaso Simoncini

Research output: Contribution to journal › Letter › Other › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	49-55
Number of pages	7
Journal	Post Reproductive Health
Volume	27
Issue number	1
DOIs	https://doi.org/10.1177/2053369120983154
Publication status	Published - Mar 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/2053369120983154

Cite this

Hamoda, H., Davis, S. R., Cano, A., Morris, E., Davison, S., Panay, N., Lumsden, M. A., Hillard, T., & Simoncini, T. (2021). BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020. Post Reproductive Health, 27(1), 49-55. https://doi.org/10.1177/2053369120983154

Hamoda, Haitham ; Davis, Susan R. ; Cano, Antonio ; Morris, Edward ; Davison, Sonia ; Panay, Nicholas ; Lumsden, Mary A. ; Hillard, Tim ; Simoncini, Tommaso. / BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020. In: Post Reproductive Health. 2021 ; Vol. 27, No. 1. pp. 49-55.

@article{2b40a4bbbf0643838017e1da8d4c9d43,

title = "BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020",

author = "Haitham Hamoda and Davis, {Susan R.} and Antonio Cano and Edward Morris and Sonia Davison and Nicholas Panay and Lumsden, {Mary A.} and Tim Hillard and Tommaso Simoncini",

year = "2021",

month = mar,

doi = "10.1177/2053369120983154",

language = "English",

volume = "27",

pages = "49--55",

journal = "Post Reproductive Health",

issn = "2053-3691",

publisher = "SAGE Publications Ltd",

number = "1",

}

Hamoda, H, Davis, SR, Cano, A, Morris, E, Davison, S, Panay, N, Lumsden, MA, Hillard, T & Simoncini, T 2021, 'BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020', Post Reproductive Health, vol. 27, no. 1, pp. 49-55. https://doi.org/10.1177/2053369120983154

BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020. / Hamoda, Haitham; Davis, Susan R.; Cano, Antonio; Morris, Edward; Davison, Sonia; Panay, Nicholas; Lumsden, Mary A.; Hillard, Tim; Simoncini, Tommaso.

In: Post Reproductive Health, Vol. 27, No. 1, 03.2021, p. 49-55.

Research output: Contribution to journal › Letter › Other › peer-review

TY - JOUR

T1 - BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020

AU - Hamoda, Haitham

AU - Davis, Susan R.

AU - Cano, Antonio

AU - Morris, Edward

AU - Davison, Sonia

AU - Panay, Nicholas

AU - Lumsden, Mary A.

AU - Hillard, Tim

AU - Simoncini, Tommaso

PY - 2021/3

Y1 - 2021/3

UR - http://www.scopus.com/inward/record.url?scp=85099556454&partnerID=8YFLogxK

U2 - 10.1177/2053369120983154

DO - 10.1177/2053369120983154

M3 - Letter

C2 - 33459135

AN - SCOPUS:85099556454

VL - 27

SP - 49

EP - 55

JO - Post Reproductive Health

JF - Post Reproductive Health

SN - 2053-3691

IS - 1

ER -

BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020

UN SDGs

Access to Document

Other files and links

Cite this